Initiation of sacubitril/valsartan in hospitalized patients with HFrEF after hemodynamic stabilization: baseline characteristics of the TRANSITION study compared with TITRATION and PARADIGM-HF

Senni M.¹ , Wachter R.² , Belohlavek J.³ , Witte K.⁴ , Strabuzynska-Migaj E.⁵ , Kobalava Z. ⁶ , Fonseca C.⁷ , Noe A.⁸ , Butylin D.⁸ , Schwende H.⁸ , Pascual-Figal D.⁹

European Heart Journal

Английский

1392-1393

Опубликовано

39

2018

• ¹ Osped Papa Giovanni XXIII, Heart Failure & Transplant Unit, Bergamo, Italy
• ² Leipzig Univ Hosp, Clin & Policlin Cardiol, Leipzig, Germany
• ³ Charles Univ Prague, Prague, Czech Republic
• ⁴ Univ Leeds, Leeds Inst Cardiovasc & Metab Med, Leeds, W Yorkshire, England
• ⁵ Poznan Univ Med Sci, Dept Cardiol 1, Poznan, Poland
• ⁶ Peoples Friendship Univ Russia RUDN Univ, Moscow, Russia
• ⁷ Hosp Sao Francisco Xavier, CHLO, Heart Failure Unit, Dept Internal Med, Lisbon, Portugal
• ⁸ Novartis Pharma AG, Basel, Switzerland
• ⁹ Hosp Clin Univ Virgen de la Arrixaca, Dept Cardiol, Murcia, Spain

19.07.2019

20.01.2022

https://repository.rudn.ru/ru/records/article/record/39327/